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ABSTRACT
Background The benefit of endovascular 
thrombectomy for acute ischemic stroke with M2 
segment middle cerebral artery occlusion remains 
controversial, with uncertainty and paucity of data 
specific to this population.
Objective To compare outcomes between M1 and 
M2 occlusions in the Analysis of Revascularization in 
Ischemic Stroke with EmboTrap (ARISE II) trial.
Methods We performed a prespecified analysis of 
the ARISE II trial with the primary outcome of 90- day 
modified Rankin Scale score of 0–2, which we termed 
good outcome. Secondary outcomes included reperfusion 
rates and major adverse events. The primary predictor 
was M2 occlusion, which we compared with M1 
occlusion.
Results We included 183 patients, of whom 126 (69%) 
had M1 occlusion and 57 (31%) had M2 occlusion. There 
was no difference in the reperfusion rates or adverse 
events between M2 and M1 occlusions. The rate of good 
outcome was not different in M2 versus M1 occlusions 
(70.2% vs 69.7%, p=0.946). In a logistic regression 
model adjusted for age, sex, and baseline National 
Institutes of Health Stroke Scale score, M2 occlusions did 
not have a significantly different odds of good outcome 
compared with M1 occlusions (OR 0.94, 95% CI 0.47 to 
1.88, p=0.87).
Conclusion In ARISE II, M2 occlusions achieved a 
70.2% rate of good outcome at 90 days, which is 
above published rates for untreated M2 occlusions and 
superior to prior reports of M2 occlusions treated with 
endovascular thrombectomy. We also report similar rates 
of good outcome, successful reperfusion, death, and 
other adverse events when comparing the M1 and M2 
occlusions.
INTRODUCTION
The benefit of endovascular thrombectomy (EVT) 
for acute ischemic stroke (AIS) caused by M2 
segment middle cerebral artery (MCA) occlusion 
has not been evaluated in a randomized controlled 
trial specific to that population. The natural history 
of an untreated M2 occlusion, although not as 
ominous as an untreated M1 segment or internal 
carotid artery occlusion, is nonetheless poor. Fewer 
than half of patients achieve functional indepen-
dence by 90 days.1 A small number of patients 
with AIS with M2 occlusion were included in the 
landmark EVT trials, and multiple retrospective 
studies and meta- analyses have been published, all 
of which show benefit for EVT.2–6 A meta- analysis 
of the Highly Effective Reperfusion evaluated in 
Multiple Endovascular Stroke (HERMES) trials 
database, which included pooled data from several 
of the landmark EVT trials, showed that patients 
with AIS with M2 occlusion who received EVT had 
significantly better 90- day outcomes than patients 
with an M2 occlusion who did not undergo EVT.7
The Analysis of Revascularization in Ischemic 
Stroke with EmboTrap (ARISE II) trial reported that 
the EmboTrap revascularization device achieved 
high rates of successful reperfusion and good func-
tional outcome with minimal adverse events.8 A 
quarter of the patients enrolled in ARISE II had 
M2 occlusion, which was permissible in the trial 
because the 0.021” microcatheter compatibility 
of EmboTrap allowed entry into the M2 segment. 
Given the ongoing uncertainty about the efficacy 
of EVT for M2 occlusions and lack of data specific 
to EmboTrap in this population, we performed a 
subgroup analysis of ARISE II to compare rates of 
successful reperfusion, adverse events, and good 
outcome between M1 and M2 occlusions.
METHODS
Cohort
We performed a prespecified analysis of the ARISE 
II trial, an open- label, single- arm, multicenter, 
prospective clinical study designed to evaluate 
the safety and efficacy of the EmboTrap device in 
patients with AIS compared with efficacy rates for 
two FDA- approved stent retriever devices.8 The 
data for this analysis were de- identified, which did 
not require institutional review board approval. All 
data relevant to the study are included in the article 
or uploaded as online supplemental information.
The EmboTrap revascularization device (Neuravi/
Cerenovus, Galway, Ireland) is a dual- layer stent 
retriever, engineered with articulating petals, 
and a distal capture zone for effectively trapping, 
retaining, and removing large vessel occlusive 
clots causing AIS. Key ARISE II inclusion criteria 
included pre- stroke modified Rankin Scale (mRS) 
score ≤1, baseline National Institutes of Health 
Stroke Scale (NIHSS) score ≥8 and ≤25, Alberta 
Stroke Program Early CT Score (ASPECTS) ≥6 or 
core infarct volume <50 mL on MRI or CT- based 
imaging (for anterior circulation strokes), and treat-
ment with intravenous tissue- type plasminogen 
activator, if eligible, within 3 hours of stroke onset. 
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Ischemic stroke
For our analysis, we included ARISE II patients with angiograph-
ically confirmed M1 and M2 MCA occlusion and excluded those 
with posterior circulation or internal carotid artery occlusion.
Outcomes and predictors
The primary outcome of our analysis was good functional 
outcome defined as an mRS score of 0–2 at 90 days from stroke 
onset. The secondary outcomes included: (1) successful reper-
fusion, defined as modified thrombolysis in cerebral infarction 
(mTICI) score ≥2 b, ≥2c, and 3 after the first pass, last of up to 
three passes (ARISE II primary endpoint), and final pass; (2) the 
ordinal categories of the mRS; (3) good outcome defined as mRS 
score 0–1 at 90 days; and (4) major adverse events, including 
death within 90 days, symptomatic intracranial hemorrhage, and 
procedure- related serious adverse events. The imaging core labo-
ratory defined mTICI for M2 occlusions based on the percentage 
reperfusion of the territory supplied by the occluded M2.
The primary predictor is M2 occlusion, which we compared 
with M1 occlusion because of its similarity in phenotype and 
procedural approach. We also analyzed our outcomes by the 
following imaging core laboratory adjudicated stratifications: 
dominant versus non- dominant M2 and proximal versus distal 
M2 origin. The following definitions were applied: dominant 
M2 (supplying ≥50% of the MCA territory), non- dominant M2 
(supplying <50% of the MCA territory), proximal M2 (assessed 
on coronal images; origin proximal to the mid- sylvian point), 
and distal M2 (origin distal to the mid- sylvian point).7
Statistical analysis
Categorical data are presented as proportions, normally distrib-
uted continuous data as mean with SD, and ordinal data as 
median with IQR. Subject characteristics at enrollment were 
summarized by the full cohort and the subgroups of M1 versus 
M2 occlusion. We tested for intergroup differences in the M1/2 
occlusion subgroups, M2 stratifications, and in our primary and 
secondary outcomes with the χ2 test or Fisher’s exact test (due 
to expected cell sizes <5) as appropriate for binary variables, the 
Wilcoxon rank- sum test for ordinal variables, and Student’s t- test 
or a Satterthwaite approximation in cases of unequal variances 
as appropriate for continuous variables. We fitted multivariate 
logistic regression models with covariates that were chosen from 
patient age (reference <75 years), sex (reference female), NIHSS 
score at admission, and time from symptom onset or last known 
well to arterial puncture using least absolute shrinkage and selec-
tion operator variable selection.
RESULTS
The ARISE II study enrolled 244 patients, of which we included 
183 (see figure 1). In our cohort, 126 (69%) had M1 occlu-
sion and 57 (31%) had M2 occlusion. Baseline demographics 
are shown in table 1. The patients with an M2 occlusion were 
significantly older than M1 occlusion patients (71.2 vs 66.9 
years, p=0.033) and had a lower mean NIHSS score (14.4 vs 
15.9, p=0.051).
For categorical variables, p values are generated using a χ2 
test or a Fisher’s exact test (due to expected cell sizes <5), as 
appropriate.
There was no difference in the imaging core laboratory 
adjudicated reperfusion rates between M1 and M2 occlusions 
(online supplemental table 1). The rates of mTICI score ≥2c 
at the first pass, last of up to three passes, and final pass were 
38.6%, 64.9%, and 73.7% for M2 occlusions. These rates did 
not differ compared with M1 occlusions (all p values ≥0.7). We 
did observe a higher percentage of mTICI scores of 3 after the 
final pass for M2 occlusion than for M1 occlusion (56.1% vs 
46.8%, p=0.243), but it did not reach statistical significance.
All serious procedure- related adverse events are shown in 
table 2. The rates of serious adverse events adjudicated by the 
ARISE- II Clinical Events Committee, including procedure- 
related complications, procedure- related mortality, and symp-
tomatic intracranial hemorrhage within 24 hours of stroke onset, 
were not significantly different between M1 and M2 occlusions 
(table 2). Additional adverse events, including adjudication 
of relatedness to the study intervention, are shown in online 
supplemental table 2, including the Heidelberg Bleeding Clas-
sification of postprocedural hemorrhage.9 No serious adverse 
Figure 1 Study flow chart showing the derivation of our cohort.
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events adjudicated by the Clinical Events Committee were found 
to be related to the EmboTrap device.
A 90- day mRS score was available in 179/183 patients in our 
cohort. Good outcome (mRS score 0–2) was present in 125/179 
(69.8%) of patients, and the rate was not different in M2 vs 
M1 occlusion (70.2% vs 69.7%, p=0.946). The percentage of 
patients in the individual categories of the 90 day mRS score was 
balanced (table 3), as was the percentage with a 90- day mRS of 
0–1 (M2 vs M1 occlusion, 57.9% vs 54.9%, p=0.709).
In a multivariate logistic regression model adjusted for age, 
sex, and NIHSS, M2 occlusion did not have an association 
with good outcome (OR 0.94, 95% CI 0.47 to 1.88, p=0.87). 
In a multivariate logistic regression model adjusted for age and 
NIHSS, M2 occlusion also did not have an association with 
Table 1 Baseline demographic data for the full cohort (n=183), and after stratification by M1 (n=126) and M2 (n=57) middle cerebral artery 
(MCA) occlusions
Demographic data
All subjects
(n=183)
MCA M1
(n=126)
MCA M2
(n=57) P value
Age at enrollment, years
  Mean (SD) 68.2 (12.9) 66.9 (13.1) 71.2 (12.0) 0.0330
  Median 70 69 75
  Min to max 20 to 86 23 to 85 20 to 86
  ≥75, N (%) 74 (40.4) 45 (35.7) 29 (50.9) 0.0529
  <75, N (%) 109 (59.6) 81 (64.3) 28 (49.1)
Sex, N (%)
  Male 87 (47.5) 57 (45.2) 30 (52.6) 0.3537
  Female 96 (52.5) 69 (54.8) 27 (47.4)
NIHSS score at presentation
  Mean (SD) 15.42 (4.42) 15.90 (4.41) 14.37 (4.31) 0.0507
  Median 16 16 14
  Q1 to Q3 12 to 19 12 to 19 12 to 18
  Min to max 7 to 26 8 to 26 7 to 23
Baseline ASPECTS
  N 168 117 51
  Mean (SD) 9.38 (1.16) 9.38 (1.22) 9.37 (1.00) 0.3723
  Median 10.00 10.00 10.00
  Q1 to Q3 9.00 to 10.00 9.00 to 10.00 9.00 to 10.00
  Min to max 4.00 to 10.00 4.00 to 10.00 5.00 to 10.00
Pre- stroke mRS score, N (%)
  0 139 (76.0) 96 (76.2) 43 (75.4) 0.8983
  1 43 (23.5) 29 (23.0) 14 (24.6)
  2 1 (0.5) 1 (0.8) 0
Occlusion side, left, N (%) 87 (47.5) 57 (45.2) 30 (52.6) 0.3537
Symptom onset or LKW to arterial puncture, min
  N 140 95 45
  Mean (SD) 201.59 (77.28) 198.72 (76.26) 207.64 (79.93) 0.5251
  Median 195 187 214
Hypertension, N (%) 127 (69.4) 85 (67.5) 42 (73.7) 0.3975
Diabetes mellitus, N (%) 37 (20.2) 25 (19.8) 12 (21.1) 0.8501
Atrial fibrillation, N (%) 72 (39.3) 47 (37.3) 25 (43.9) 0.4003
Hyperlipidemia, N (%) 80 (43.7) 50 (39.7) 30 (52.6) 0.1020
Smoking, N (%) 48 (26.2) 36 (28.6) 12 (21.1) 0.2843
Previous MI/CAD, N (%) 39 (21.3) 30 (23.8) 9 (15.8) 0.2199
Previous stroke, N (%) 33 (18.0) 21 (16.7) 12 (21.1) 0.4748
Intravenous tPA failure, N (%) 123 (67.2) 85 (67.5) 38 (66.7) 0.9157
For continuous variables, p values are generated using a t- test, with a Satterthwaite approximation in cases of unequal variances.
For ordinal variables (NIHSS score at presentation, baseline ASPECTS), p values are generated using the Wilcoxon rank- sum test.
ASPECTS, baseline Alberta Stroke Program Early CT score; CAD, coronary artery disease; IA, intra- arterial; IV, intravenous; LKW, last known well; MCA, middle cerebral artery; MI, 
myocardial; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale/Score; tPA, tissue plasminogen activator.
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mRS score 0–1 (OR 0.92, 95% CI 0.43 to 1.96, p=0.83) or all- 
cause mortality (OR 1.43, 95% CI 0.43 to 4.70, p=0.56) (online 
supplemental table 3).
There were 33/57 (57.9%) patients with a dominant M2 versus 
24/57 (42.1%) with a non- dominant M2, and 27/57 (47.4%) 
with a proximal M2 origin versus 30/57 (52.6%) with a distal 
M2 origin. The angiographic and functional outcomes were not 
significantly different in these M2 stratifications (table 4).
DISCUSSION
The rate of good functional outcome, successful reperfusion, 
and adverse events did not differ significantly between M1 and 
M2 occlusions in patients with AIS treated with the EmboTrap 
device in ARISE II. Among the 833 patients randomized to 
EVT in the seven major EVT trials published since 2015 (MR 
CLEAN, ESCAPE, EXTEND- IA, SWIFT PRIME, REVASCAT, 
DAWN, DEFUSE 3), only 55 patients had an M2 occlusion.10–16 
In ARISE II, we enrolled 57 patients with M2 occlusion, which 
represents a larger sample size. Accordingly, these results are 
important given the rigor of outcome adjudication in ARISE 
II and the lack of data specific to the EmboTrap device. Prior 
studies have established that the M2 segment is a common site 
of large vessel occlusion that can cause significant morbidity, and 
the expansion of EVT to this patient population could improve 
stroke outcomes.17
Compared with patients with AIS with untreated M2 occlu-
sion, EVT with the EmboTrap device almost doubled the 
percentage of patients who achieve a good outcome (70.2%). 
In the HERMES database there were 62 patients with 
untreated M2 occlusion, derived from control arms of clinical 
trials.7 Those patients had a 39.7% rate of good outcome at 90 
days. A multicenter retrospective study by Sarraj et al had 234 
patients with untreated M2 occlusion, who had a 35.4% rate 
of good outcome at 90 days.3 In a final study of the RESUCE- 
Japan Registry 2 cohort, there were 188 untreated M2 occlu-
sions, who had a higher 50.5% rate of good outcome at 90 
days.18 Compared with previously reported data, the outcomes 
for patients with M2 occlusion with AIS treated with EVT 
in ARISE II were excellent. For example, in ARISE II, good 
outcome (mRS score 0–2) at 90 days was seen in 70.2% of 
M2 occlusions. In the HERMES, Sarraj, and RESCUE- Japan 
studies, M2 occlusion treated with EVT achieved a rate of 
good outcome of 58.2%, 62.8%, and 57.1%, respectively. In 
two meta- analyses comparing EVT in M1 versus M2 occlu-
sions,5 6 the rate of good outcome for M2 occlusions was 59%. 
All these studies also reported the safety of EVT for M2 occlu-
sions, similar to the data we report.
Table 2 Serious procedure- related adverse events as determined by 
the Clinical Events Committee
Adverse events
MCA M1
(n=126)
MCA M2
(n=57) P value*
Procedure- related serious adverse 
events
4 (3.2%) 5 (8.8%) 0.1396
Postprocedural subarachnoid 
hemorrhage
2 (1.6%) 2 (3.5%) 0.5896
Vessel perforation 2 (1.6%) 0 (0%) 1.0000
Carotid artery dissection 0 (0%) 1 (1.8%) 0.3115
Cerebral artery occlusion 0 (0%) 1 (1.8%) 0.3115
Ischemic stroke (iatrogenic) 1 (0.8%) 0 (0%) 1.0000
Neurological decompensation 0 (0%) 1 (1.8%) 0.3115
Vessel puncture site hemorrhage 0 (0%) 1 (1.8%) 0.3115
Vessel puncture site thrombosis 0 (0%) 1 (1.8%) 0.3115
Symptomatic intracranial hemorrhage 
within 24 hours
6 (4.8%) 2 (3.5%) 1.0000
Procedure- related mortality
(at 7 days postprocedure)
0 0 –
*For categorical variables, p values are generated using a χ2 test or a Fisher’s exact 
test (due to expected cell sizes <5), as appropriate.
MCA, middle cerebral artery.
Table 3 Modified Rankin Scale (mRS) scores at 90 days, which were 
available in 122 patients with M1 and 57 patients with M2 middle 
cerebral artery (MCA) occlusions
MCA M1
(n=122)
MCA M2
(n=57) P value*
Good outcome (90 day mRS score 0–2), 
n (%)
85 (69.7) 40 (70.2) 0.9455
90- Day mRS score, n (%)
  0 37 (30.3) 16 (28.1) 0.9358
  1 30 (24.6) 17 (29.8)
  2 18 (14.8) 7 (12.3)
  3 9 (7.4) 4 (7.0)
  4 15 (12.3) 5 (8.8)
  5 5 (4.1) 2 (3.5)
  6 8 (6.6) 6 (10.5)
90- Day mRS score 0–1, n (%) 67 (54.9) 33 (57.9) 0.7087
*For categorical variables, p- values are generated using a χ2 test or a Fisher’s exact 
test (due to expected cell sizes<5) as appropriate.
Table 4 Primary outcomes in stratifications of patients with M2 occlusions, including dominant versus non- dominant M2 and proximal versus 
distal M2 origin
Outcome
Dominant
(n=33)
Non- Dominant
(n=24) P value*
Proximal
(n=27)
Distal
(n=30) P value*
Good outcome (90 day mRS score 0–2) 22 (66.7%) 18 (75.0%) 0.4971 17 (63.0%) 23 (76.7%) 0.2588
90- Day mRS 0–1 20 (60.6%) 13 (54.2%) 0.6269 14 (51.9%) 19 (63.3%) 0.3807
All- cause mortality at 90 days 2 (6.1%) 4 (16.7%) 0.2275 3 (11.1%) 3 (10.0%) 1.0000
Final pass mTICI ≥2b 30 (90.9%) 22 (91.7%) 1.0000 25 (92.6%) 27 (90.0%) 1.0000
Final pass mTICI ≥2c 24 (72.7%) 18 (75.0%) 0.8474 18 (66.7%) 24 (80.0%) 0.2537
Final pass mTICI 3 16 (48.5%) 16 (66.7%) 0.1720 16 (59.3%) 16 (53.3%) 0.6526
*For categorical variables, p values are generated using a χ2 test or a Fisher’s exact test (due to expected cell sizes<5) as appropriate.
mTICI, modified thrombolysis in cerebral infarction .
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Both meta- analyses reported that EVT- treated patients with 
AIS with an M2 occlusion had better outcomes than patients 
with an M1 occlusion.5 6 In ARISE II, we found no difference in 
good outcome, reperfusion, or adverse events between patients 
with M1 and M2 occlusion, although patients in our cohort with 
M2 occlusion did have a lower mean NIHSS score and a trend 
towards a higher baseline ASPECT score. The primary results 
publication of ARISE II had a table in the online supplemental 
materials that compared its cohort to that of 11 other studies, 
and found that the ARISE II cohort had a shorter time from 
stroke onset or last known normal to EVT treatment.8 Time 
from stroke onset to reperfusion is a critical factor in the odds 
of achieving good outcome.19 20 The comparatively favorable 
outcomes for the M1 occlusions in ARISE II may reflect their 
earlier reperfusion. The EmboTrap also demonstrated higher 
than average rates of successful reperfusion, which may account 
for the better outcomes in this cohort.8 Finally, in a meta- analysis 
of the five randomized controlled trials from 2015 (MR CLEAN, 
ESCAPE, REVASCAT, SWIFT PRIME, and EXTEND IA), the 
median (IQR) ASPECT score of EVT- treated patients was 97–10 21 
while in ARISE II it was 10 (9-10). This introduces the possibility 
that the better outcomes in ARISE II patients were due to smaller 
infarct volumes prior to EVT.
The present study has several limitations. The most important 
being that although this was a prespecified analysis, it is a 
subgroup of ARISE II with a limited number of M2 occlusions. 
We also present the results of a study where only one thrombec-
tomy device was used, which limits the generalizability of our 
findings. Another limitation is that four patients were lost to 
follow- up in the M1 occlusion subgroup compared with none 
in the M2 occlusion subgroup, which might have introduced 
bias. Furthermore, the lack of a comparator or control group 
in ARISE II allows comparison only with published cohorts. A 
direct comparison would be necessary to draw conclusions about 
the relative efficacy of the EmboTrap for M2 occlusions. These 
limitations are offset by several strengths—in particular, the use 
of a clinical outcome and central imaging adjudication process 
for reperfusion and intracranial hemorrhage with at least two 
independent raters who were not involved in the trial. In addi-
tion, the imaging core laboratory adjudicated mTICI score after 
the first three and final endovascular thrombectomy passes, 
provided data on the full spectrum of mTICI scores (including 
2c), and was blinded to clinical outcomes. Safety events were 
adjudicated by an independent Clinical Events Committee also 
blinded to clinical data.
CONCLUSION
In ARISE II, the EmboTrap device successfully treated M2 
MCA occlusions in patients with AIS, achieving a 70.2% rate 
of good outcome at 90 days, which is well above published 
rates for untreated M2 occlusions and also superior to prior 
reports of EVT- treated M2 occlusions. When comparing the 
M1 and M2 occlusions in ARISE II, we report similar rates of 
good outcome, successful reperfusion, death, and other adverse 
events. The treatment of M2 occlusion in patients with AIS with 
the EmboTrap device appears safe and efficacious.
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